Introduction. We describe a simplified distributional cost-effectiveness analysis based on aggregate data to estimate the health inequality impact of public health interventions. Methods. We extracted data on costs, health outcomes expressed as quality-adjusted life years (QALYs), and target populations for interventions within National Institute for Health and Care Excellence (NICE) public health guidance published up to October 2016. Evidence on variation by age, gender, and index of multiple deprivation informed socioeconomic distributions of incremental QALYs, health opportunity costs, and the baseline distribution of health. Total population QALYs, summary measures of inequality, and a health equity impact plane show results by intervention and by guideline. A value for inequality aversion from a general population survey in England let us combine impacts on health inequality and total health into a single measure of intervention value. Results. Our estimates suggest that of 134 interventions considered by NICE, 70 (52%) reduce inequality and increase health, 21 (16%) involve a tradeoff between improving health and improving health inequality, and 43 (32%) reduce health and increase health inequality. Fully implemented, the potential impact of all recommendations was 23,336,181 additional QALYs for the population of England and Wales and a reduction of the gap in quality-adjusted life expectancy between the healthiest and least healthy from 13.78 to 13.34 QALYs. The combined value of the additional health and reduction in inequality was 28,723,776 QALYs. Discussion. Our analysis takes account of the fact that existing public health spending likely benefits the most disadvantaged. This simple method applied separately to economic evaluation produces evidence of intervention impacts on the distribution of health that is vital in determining value for money when health inequality reduction is a policy goal.
In the United Kingdom, no formal approach prescribes how health inequality impacts should inform public health investment decisions. In England, women and men in the most deprived areas live up to 9 years fewer and have up to 20 fewer years in good health compared to those in the least deprived areas. 1 The reduction of health inequalities associated with socioeconomic factors is a prominent social goal, demonstrating that societies regard these inequalities as unfair and value lessening of inequalities alongside improving health. 2, 3 It has been argued that public health interventions can tackle this objective through their focus on lifestyle changes and other social determinants of health. 4, 5 Centre for Health Economics, University of York, York, UK (SG, JLK); Health Economics and Decision Science, University of Sheffield, Sheffield, UK (BP); and National Institute for Health and Care Excellence, London, UK (LO). The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Financial support for this study was provided entirely by a contract with the National Institute for Health and Care Excellence (NICE). The funding agreement ensured the authors' independence in designing the study, interpreting the data, and writing and publishing the report. The following authors were employed by NICE while the research was undertaken: Becky Pennington and Lesley Owen.
The National Institute for Health and Care Excellence (NICE) produces public health guidelines that recommend interventions for provision by national and local health care commissioners or within the wider public and private sectors. NICE's equality objectives note that public health guidance in particular is concerned with tackling health inequalities associated with underlying socioeconomic factors and with inequities in access for certain disadvantaged groups. 6 The current guidance does not describe a process by which public health advisory committees (PHACs) should take account of the impact on health inequalities in their recommendations. A formal review of the available evidence supported with expert testimony and economic evaluation informs their recommendations. The economic evaluations estimate the scale of the health benefits produced for a given investment in an intervention. The PHACs make a judgment about whether the health benefits are valuable compared to alternative uses of the same resources. However, the economic evaluations do not currently evaluate the distribution of outcomes within the population.
Evidence on the health inequality impact of interventions presented to PHACs is typically qualitative and pertains to the characteristics of the target population. This informs the likely socioeconomic distribution of the benefits of the intervention but fails to account for the distribution of the benefits produced by investing the intervention costs in other public health activities. This omission of opportunity cost prevents estimation of the magnitude of the inequality impact. The socioeconomic distribution of health opportunity costs depends on the characteristics of individuals who benefit from existing services. Where health inequalities are a policy concern, the magnitude of the net health inequality impact is relevant to determining value for money. Producing recommendations without information on health inequality impacts risks failing to promote the most valuable interventions.
In principle, a formal distributional cost-effectiveness analysis could evaluate health inequality impacts to support each public health guideline. 7, 8 In the absence of bespoke distributional analysis, we demonstrate a method for conducting quantitative inequality impact assessment using available aggregate data. We apply this to NICE guidelines conducted between 2006 and 2016 to estimate how the public health interventions considered affect the distribution of health, taking into account variation in health outcomes by age, gender, and socioeconomic groups.
Methods
The methods are based on distributional costeffectiveness analysis, and we focus on change in lifetime health inequality across the whole population. 7 Figure 1 shows the steps in combining information on additional costs and health outcomes produced by standard economic evaluation with routine data about the distribution of targeted health problems and prior knowledge of health opportunity costs, according to age, gender, and socioeconomic status. In essence, this scales up average costs and health outcomes using patient population numbers and disaggregates them to describe the distribution of health benefits by age, gender, and socioeconomic status. We show the calculations for public health guideline 43 (hepatitis B and C testing) in Box 1. Combining the distributions of intervention impacts with a baseline distribution of health shows how interventions and public health recommendations might affect lifetime health inequality in the English population. We used qualityadjusted life years (QALYs) and quality-adjusted life expectancy (QALE) as our measure of health and the Index of Multiple Deprivation (IMD) as our measure of socioeconomic status. This guideline contributed 5 interventions to the analysis. This worked example focused on one: the use of dried blood spot testing in specialist addiction services.
1. The economic evaluation reported total incremental costs of £917,478 and incremental quality-adjusted life years (QALYs) of 63.
The target population was injecting drug users (IDUs), aged 15 to 59, in contact with specialist services. The economic evaluation submitted to the National Institute for Health and Care Excellence (NICE) indicated that 0.65% of the population aged 15 to 59 are current IDUs, 25% of whom are undiagnosed and in contact with specialist addiction services. We multiply these by the 2011 UK census figure of 37,899,000 individuals aged 15 to 59 to obtain a target population size of 61,586. Note that if per-person incremental costs (£14.90) and QALYs (0.001) had been reported, these would have been multiplied by population size.
We describe 7 stages of analysis:
1. Extract incremental costs and health benefits and size of the target population 2. Estimate the distribution of population health benefits by gender and socioeconomic status 3. Convert population costs into health opportunity costs 4. Estimate the distribution of population health opportunity cost by gender and socioeconomic status 5. Calculate the net health impact (health benefit minus health opportunity cost) for gender and socioeconomic subgroups 6. Combine net health impacts with a baseline distribution of lifetime health 7. Calculate inequality measures on the pre-and postintervention health distributions to summarize health inequality impact
Extract Incremental Costs and Health Benefits and Size of the Target Population
We reviewed cost-effectiveness evidence and the associated PHAC recommendations for NICE public health guidance issued between March 2006 and October 2016. We extracted information from guidance documents, economic modeling reports, and costing templates. We excluded guidelines if 1) no economic modeling was conducted, 2) the economic modeling did not use QALYs as a health outcome measure, 3) incremental costs and QALYs were not reported separately, 4) hypothetical analyses were conducted rather than modeling specific interventions, and 5) the guideline was obsolete.
For each intervention, we extracted the PHAC recommendation and the per-recipient incremental costs and QALYs that formulated the base-case incremental costeffectiveness ratios. These represent the present value of the costs and QALYs accruing over the time horizon of the underlying cost-effectiveness analysis, for which the NICE reference case indicates the use of an annual discount rate of 3.5%. To estimate the number of recipients, we extracted population size estimates from NICE documentation and, if unavailable, from alternative sources, including previously published studies and national population statistics. Where no specific intervention was explicit in PHAC recommendations, we used the committee's consideration of the cost-effectiveness evidence
2. This guideline targets the diseases hepatitis B and C, which map to International Classification of Diseases (ICD) codes B17, B18, and B19.
The subgroup sizes are determined using the proportion of National Health Service (NHS) activity by gender and ICD code. We report the calculations for females, who constitute 48% of all NHS activity in this ICD code. The same approach applied to males provides the subgroup sizes within the remaining 52%.
The distribution of NHS hospital activity by index of multiple deprivation (IMD) quintile for females in these ICD codes, in order from most deprived to least deprived, is 0.14, 0.11, 0.11, 0.07, and 0.06.
3. The same health opportunity cost of 1 QALY per £20,000 applies for all interventions. The total population cost in terms of health opportunity costs is £917,478/£20,000 = 46 QALYs. 4 . The distribution of this opportunity cost is the same for all interventions. In females, the order from most deprived to least deprived IMD quintile is 0.14, 0.12, 0.12, 0.09, and 0.08. to inform assumptions about whether the intervention would fall under the general recommendation. Where the economic evidence included a range rather than a single estimate of cost-effectiveness for an intervention, we extracted the best and worst case, with the best case used for our primary analysis.
Estimate the Distribution of Population Health Benefits by Gender and Socioeconomic Status
We multiplied the target population size by the perperson QALY gain to calculate the incremental population health benefit for each intervention. This value represents the upper limit of health gains as it entails every person in the eligible population receiving the intervention (i.e., 100% reach and 100% implementation) and does not account for any proportion of the population that may already be in receipt of the intervention.
To estimate the size of each gender and socioeconomic subgroup within a target population, we first categorized interventions as 1) targeting specific diseases, such as type 2 diabetes; 2) targeting health behaviors, such as smokers; or 3) targeting disadvantaged groups, such as lowincome or high-deprivation populations.
For interventions targeting diseases, we mapped those diseases to 3-digit International Classification of Disease (ICD) codes. We then calculated subgroup sizes based Intervention costs are converted into health opportunity costs at a rate of one QALY per £20,000.
on the corresponding proportion of National Health Service (NHS) hospital activity by gender, index of multiple deprivation (IMD), and ICD code for that group using Hospital Episode Statistics (HES) (2011-2012 and 2012-2013 ). For interventions targeted by age, we used data from the relevant age band. Where interventions targeted behaviors, we searched for data sources that reported behavior distribution by gender and IMD. For interventions specifically targeting low-income, disadvantaged, or deprived groups, we made a simplifying assumption that the health benefits would accrue to the most deprived fifth of the population in terms of IMD.
Convert Population Costs into Health Opportunity Costs
We calculated incremental population costs by multiplying the target population size by the per-person incremental cost. As costs represent investments that could be spent elsewhere-namely, other public health interventions-we converted them into health losses using an estimate of the health opportunity cost per pound of public-sector expenditure. This value signifies the cost per QALY of services that could otherwise have been funded (or can be introduced if a public health intervention is cost saving). We use a value of £20,000 per QALY for the base case analysis, which corresponds to the lower bound of the health sector cost-effectiveness threshold used within NICE. 10 If this figure is overestimated or if public health activities are more efficient than medical care activities, this value underestimates health opportunity costs.
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Estimate the Distribution of Population Health Opportunity Cost by Gender and Socioeconomic Status
We found no published estimate of the socioeconomic gradient for marginal changes in public health expenditure, and so we assumed the same gradient as observed in NHS-funded interventions. The gender and socioeconomic distribution of population health gains from marginal changes in NHS expenditure has recently been estimated. 14 We use this to represent the distribution of the health benefits that would have been produced by alternative public health interventions. The distribution provides the proportion of the marginal QALY gain that would accrue to each gender and IMD subgroup, and when multiplied by the population health opportunity costs for each intervention, this provides the subgroup health opportunity costs.
Calculate the Net Health Impact for Gender and Socioeconomic Subgroups
The population net health impact by intervention and subgroup is the difference between the incremental population health benefits and incremental population health opportunity costs. The impact by guideline is the sum of the costs and benefits of all interventions recommended within a guideline. Where a guideline included recommendations for multiple interventions that would be mutually exclusive from an individual perspective, we assumed an even split in utilization across each intervention in the target population.
Combine Net Health Impacts with a Baseline Distribution of Lifetime Health
The baseline distribution of health represents existing health inequality by gender and socioeconomic status across the population in England and Wales. 15 The incremental net health effects of each intervention or guideline added to this baseline provide a picture of health inequality following the implementation of the intervention or guideline. This describes the impact of interventions at the level of the population of England and Wales.
Calculate Inequality Impact Measures
We chose the slope index of inequality (SII) and the relative index of inequality (RII) to summarize inequality in the distribution of health. 16 The SII is commonly used in public health research when examining absolute inequality in life expectancy by IMD. It is obtained by fitting an ordinary least squares model to estimate the slope or health gradient and interpreted as the absolute difference in QALE when moving from the least to most healthy in the population. The RII is the SII divided by the mean QALE and represents the relative change in QALE when moving from the least to most healthy. The net inequality impact is the difference between SII or RII value preand postintervention. We report the reduction such that positive values indicate interventions are estimated to reduce health inequality.
We combined the impacts on total population health and health inequality into a single indicator of value by first summarizing inequality in the distribution using the Atkinson and Kolm indices. [17] [18] [19] These indices on their own summarize the magnitude of relative and absolute inequality, respectively, and in essence assign a weight to each individual's QALE that decreases as the individual's rank in the distribution of lifetime health increases. A perfectly equal distribution of health results in an inequality index of 0, and a perfectly unequal distribution results in an index equal of 1. The weights and the value of improvements in total population health relative to the value of reduction in inequality are determined by an inequality aversion parameter, which signifies the level of concern for health inequality. The higher the inequality aversion parameter, the greater the priority to reducing health inequality compared to increasing overall health. We used inequality aversion parameters estimated in a survey of the general public in England that asked respondents to choose between an intervention that provided more health overall and one that provided less health overall but reduced the gap in health achievement between the richest and poorest. 20 The estimated inequality aversion parameters are 10.95 for the Atkinson e and 0.15 for the Kolm a. Given the initial levels of qualityadjusted life expectancy presented to study participants, these figures suggest a weight for health gains to the poorest fifth of people between 6 and 7 times as high as incremental gains to the richest fifth.
When subtracted from 1 and multiplied by the mean level of health, the Atkinson and Kolm indices can be used to summarize the value of a distribution of health in terms of the equally distributed equivalent (EDE) level of health. The EDE is the level of population health (expressed in QALYs) that, if provided uniformly to everyone in a population, would yield the same amount of social welfare to the distribution of health being evaluated. An intervention estimated to reduce health inequality will have an EDE health impact more positive than its net population health impact. Conversely, interventions that increase health inequality would have an EDE more negative than their net population health impact, with the difference showing the loss of social welfare in terms of QALYs.
Sensitivity Analyses
To assess the sensitivity of the results to the estimated cost per QALY of services that could otherwise have been funded (or introduced using resources freed up by cost-saving public health interventions), we varied the value from its base case of £20,000 between £2000 and £50,000. We explore sensitivity to the level of relative inequality aversion by varying the inequality aversion parameter used to calculate the Atkinson index from its base case of 10.95 between 0 and 20. We also investigated the differences in our results when using the costs and health estimates associated with the worst-case scenario for those interventions where multiple cost-effectiveness results were reported.
Results
The final data set consisted of 33 guidelines covering 134 discrete interventions. Details of the included guidelines (Suppl . Table S1 ), flow diagram (Suppl. Figure S1 ), and exclusions for data extraction (Suppl . Table S2) ; full results by intervention (Suppl . Table S4 ); and full results of sensitivity analyses are provided in an online supplement. Table 1 summarizes the net population health and inequality impacts of interventions, and Figure 2 and Figure 3 show the interventions' locations on the health equity impact plane, separated according to whether they were recommended by the PHAC. Estimated SII reductions varied between -0.02 and 0.36, suggesting that the maximum a single intervention could reduce the gap in QALE between the least and most healthy from its baseline value of 13.78 was by 0.36 QALYs, and at most, a single intervention could increase the gap by 0.02 QALYs. At the population level of England and Wales, the majority of interventions had small impacts on health inequality (interquartile range for change in SII, -0.0002 to 0.001). Ten percent of interventions were associated with reductions in SII of 0.06 or greater. Positive correlation was observed between net population health impact and SII reduction (Pearson correlation coefficient = 0.94). The change in Atkinson index indicated improvement in social welfare for 73 (86%) interventions recommended by the PHAC and 15 (31%) interventions that were not recommended by the PHAC. Figure 2 Health equity impact plane for public health advisory committee (PHAC) recommended interventions. Axes are subject to an inverse hyperbolic sine transformation, and reduction in slope index of inequality (SII) is multiplied by 10 4 to allow all interventions to be displayed on a single plane. Figure 3 Health equity impact plane for interventions not recommended by the public health advisory committee (PHAC). Axes are subject to an inverse hyperbolic sine transformation, and reduction in slope index of inequality (SII) is multiplied by 10 4 to allow all interventions to be displayed on a single plane. Table 2 and Figure 4 show the results of full implementation of all recommendations by guideline. Eighteen (60%) were estimated to increase total population health and reduce health inequality, 4 (13%) were estimated to reduce total population health and increase health inequality, and 8 (27%) involved a tradeoff. Estimated net population health benefits range from -1.1 million QALYs (NG6) to 10.9 million QALYs (PH50). Health inequality impacts range from an increase in SII of 0.02 (NG6) to a reduction by 0.23 (PH50). The guidelines where the value of health gains is reduced by the fact that they increase inequality in the distribution of health are PH41 and NG34 (increase in absolute inequality only) and PH17, PH20, and NG21 (increase in relative and absolute inequality). The EDE indicated that social welfare would increase from recommendations in all but 4 guidelines (PH29, PH31, PH54, NG6), all of which were associated with negative changes in population health. The potential cumulative impact across all guidelines was an additional 23, 336, 181 QALYs in the population of England and Wales and a reduction in SII of 0.44. The EDE health from full implementation of recommendations across all guidelines was 28,723,776 QALYs, implying that the inequality reduction is equivalent in worth to an additional 5.4 million QALYs.
We estimated different measures of relative inequality and absolute inequality and found little disagreement between them. For 2 guidelines (PH41 and NG34), relative inequality measured by the Atkinson index reduced while absolute inequality measured by the Kolm index and SII increased, and for 2 more (PH3 and PH24), the SII increased but the Atkinson and Kolm indexes indicated a reduction in inequality. The sensitivity analyses indicated that increasing the value of the health opportunity cost above £20,000 per QALY had little impact (Suppl. Figure S2) . However, the estimated cumulative reduction in SII fell as the cost per QALY of alternative investments reduced to 0.42 using £10,000 per QALY and to 0.27 using £2000 per QALY. The ranking of guidelines in terms of EDE health impact was sensitive to changes in the inequality aversion parameter, with a change of rank observed for 12 of 30 guidelines when the inequality aversion was increased from 0 to a value of 20 (Suppl. Figure S3 ). However, overall conclusions about the direction of change in social welfare were less sensitive and changed for only 1 of 30 guidelines. Using worst-case estimates for incremental costs and QALYs in general reduced estimated reductions in health inequality (Suppl . Table S3 ).
Discussion
The method we propose produces quantitative information on health inequality impacts from the evidence routinely provided for the formation of public health recommendations. Equally distributed equivalent health calculations place a greater value on health gains if they reduce inequality in lifetime health. This prioritizes an additional QALY to someone with low quality-adjusted life expectancy over an additional QALY to someone with high-quality adjusted life expectancy. New public health interventions are often funded with resources that would have been used for alternative public health activities, and this method ensures that health opportunity costs contribute to the estimates of net health inequality impact. The moderate positive correlation between costeffectiveness and health inequality reduction in this sample suggests that recommendations based on costeffectiveness alone might coincide with decisions that incorporate concern for health inequality but not always. Most PHAC recommendations were for interventions that reduce health inequality; where this is the case, focusing on population health gains alone routinely undervalues investment in public health interventions. This is important where public health interventions compete for funds with downstream health care interventions, which may have less scope to reduce inequality.
If health inequalities influence PHAC recommendations, a lower probability of recommendation would be expected for interventions that increase population health and increase health inequality compared to Figure 4 Health equity impact plane for public health advisory committee (PHAC) recommended interventions by guideline. Axes are subject to an inverse hyperbolic sine transformation, and reduction in slope index of inequality (SII) is multiplied by 104 to allow all guidelines to be displayed on a single plane.
those that increase population health and reduce health inequality. Similarly, we would expect a higher probability of recommendation for interventions that reduce population health but reduce health inequality compared to interventions that reduce population health and increase health inequality. The small sample of tradeoffs we found does little to inform this, and we did not search for qualitative discussion of inequality in the considerations section of the guidelines. Overall, we found that PHAC recommendations were highly concordant with social welfare. Some PHAC recommendations improved health but increased absolute inequality in health. Our analysis indicates that society values the associated increase in population health associated with these recommendations (5.6 million QALYs) sufficiently to accept the increased health inequality (increase in SII of 0.005).
We systematically extracted data from published NICE guidelines and used an empirical estimate of the socioeconomic distribution of the health opportunity cost to represent the potential harms from diverting resources from alternative activities. However, we made a number of simplifications that are worth consideration in future applications of this method. We did not attempt to characterize PHAC considerations regarding the quality of evidence or the impact of uncertainty. Our estimates represent the maximum possible impact as we did not search for evidence on differential uptake between population groups and present our results in terms of full implementation of the interventions. Where interventions are more likely to be used in least-deprived groups, as can be the case where uptake relies on individual agency, we will have overestimated reductions in health inequality. 21, 22 The method we propose can easily incorporate differential uptake by distributing the population health benefits only to the proportion of each group assumed to use the intervention.
We also did not search for evidence of differential efficacy. Determining the impact of this on health inequality impacts is not straightforward as the relationship to average QALY gains may be nonlinear and counterbalanced by interaction with differential baseline risks. Evidence for differential efficacy between population groups can guide the use of full distributional cost-effectiveness analysis in place of this simplified approach.
The value used to convert costs into health opportunity costs is a significant driver of the results, which demonstrates the importance of getting this value right for any formal appraisal process. Since opportunity costs fall heaviest on the poorest and least healthy, inequality increases with the health opportunity cost for costincreasing interventions. If the value we use is too high, we will have overestimated improvements in total population health, reduction in health inequality, and improvement in social welfare. The £20,000 per QALY used by NICE for a health sector perspective is higher than empirical estimates within the health sector. 11 The cost per QALY for a public health perspective could be lower than the health sector; the median cost per QALY for public health interventions considered by NICE is £7843. 13 The level of health inequality aversion is also uncertain and can be difficult to measure without bias. UK estimates range from 5.4 to 28.9. 23, 24 However, our results were not particularly sensitive to variation in this parameter.
We based the socioeconomic distribution of the health opportunity costs on the characteristics of beneficiaries from NHS spend. Targeting of public health interventions to disadvantaged groups could imply that the health opportunity costs fall even more on disadvantaged groups in comparison to NHS expenditure, but we did not identify evidence for this. If true, it implies that we underestimated the reduction in health inequality from cost savings and the increase in health inequality from additional costs. Our method assumes that funds used to provide public health interventions would otherwise have been spent on health-generating activities. This ignores how opportunity cost may differ where public health interventions impose costs across different sectors with interests outside of health improvement. However, previous research has shown that health care costs are the predominant category of cost impact within NICE public health guidance. 25 Previously, Owen et al. 13, 26 examined the costeffectiveness of public health interventions underpinning NICE public health guidance. Our study is the first to examine the health inequality impacts of those same interventions and follows the same principles outlined for full distributional cost-effectiveness analysis. 7 McAuley et al. 27 modeled the impact of a range of policies on population health and inequality by IMD in Scotland. They did not assume 100% reach for all interventions, but as they assumed equal uptake across population groups, their health inequality impacts would be expected to be smaller but in the same direction as our estimates. However, their analysis did not include health opportunity costs. For public health interventions, they found impacts on health inequality of similar magnitude and direction to those presented here.
Future applications of this method should seek to incorporate evidence on differential uptake and to carefully consider the implications where there exists evidence of differential effectiveness between socioeconomic groups. Ongoing research to estimate both the mean and the socioeconomic distribution of the health opportunity cost specific to public health investments and to explore how this varies across the public sector will boost the application of this method.
This method is fast, requires little data above that routinely produced to support public health guidelines, and provides information about the potential magnitude of health inequality impacts to support recommendations. The Health and Social Care Act of 2012 introduced legal duties for decisions in the NHS to be made with due regard to reduce health inequalities. Our analysis demonstrates that a simple distributional cost-effectiveness analysis framework is feasible and could provide additional information on which to base recommendations for health interventions. The proposed use is within a deliberative decision-making process that takes account of factors outside of the economic calculations, such as the quality of the underlying evidence. In the current costconstrained funding environment for public health, consideration of the socioeconomic distribution of the health opportunity cost is vital to ensure that new investments perform better than existing activities for the most disadvantaged. Showing the location of public health interventions on the health equity impact plane could draw attention to, and prompt further examination for, interventions found to have negative impacts. 28 Presenting the results using EDE health can demonstrate the added social value of reducing health inequality over and above improvements in total population health and could be a useful tool for advocating increased investment in public health.
